Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Neuroendocrine Prostate Cancer 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

pembrolizumab 3blinatumomab 2enzalutamide 1durvalumab 1dostarlimab 1cemiplimab 1atezolizumab 1abiraterone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Immune Checkpoint Inhibitors 1Hydroxyurea 1Etoposide 1Etanercept 1Cytochrome P-450 Enzyme System 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Bites and Stings × AMG 757 × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡